Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

Log in or join to add this stock to your watchlist.
Oct 18, 2019 08:32 am ET
ImmunoPrecise Adopts Shareholder Rights Plan
VICTORIA, Oct. 18, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that its Board of Directors has adopted a shareholder rights plan (the "Shareholder Rights Plan") effective October 17, 2019.  The Shareholder Rights Plan has been accepted for filing by the TSX Venture Exchange ("TSXV"), subject to certain conditions, including ratification by the Company's shareholders at its upcoming annual general meeting of shareholders scheduled to be held on November 22
Oct 03, 2019 08:00 am ET
ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom
VICTORIA, Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Dr. James Kuo, ImmunoPrecise Chairman, noted: "With the addition of Mr. Lundstrom, ImmunoPrecise further strengthens its strategic and operational commitment to industry-leading therapeutic antibody discovery for both its clients and the company's emerging internal pipeline."
Oct 01, 2019 08:00 am ET
ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer
VICTORIA, Oct. 1, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of industry professional and leader, Dr. Stefan Lang, as Chief Business Officer.  In this newly created role, Dr. Lang, who has more than 20 years of experience as a senior executive in the biotechnology industry, will be responsible for corporate and business development initiatives, as well as corporate and product strategic planning.
Sep 30, 2019 08:45 am ET
ImmunoPrecise Antibodies Announces 95.7% Investors Favored Debenture Extension and Q1 2020 Financial Results
VICTORIA, Sept. 30, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) an industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces today that it has signed extension agreements with its Debenture Holders of the amended terms and conditions on its $2,750,000 debenture that was originally issued September 26, 2018. The Company has also released its financial results for the first quarter ended July 31st, 2019. The financial statements and related management's discussion and analysis ("MD&A") can be viewed on
Sep 24, 2019 08:45 am ET
ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics
VICTORIA, Sept. 24, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, its wholly-owned subsidiary, has entered into an LOI to form a Joint Venture as it partners in the continued development of antibody therapeutics to target T cell mediated anti-tumor activity, with AgonOx, a clinical-stage biopharma company. AgonOx specializes in identifying and developing immuno-oncology therapeutics.
Sep 24, 2019 08:45 am ET
ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics
VICTORIA, Sept. 24, 2019 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, its wholly-owned subsidiary, has entered into an LOI to form a Joint Venture as it partners in the continued development of antibody therapeutics to target T cell mediated anti-tumor activity, with AgonOx, a clinical-stage biopharma company. AgonOx specializes in identifying and developing immuno-oncology therapeutics....
Sep 23, 2019 08:53 am ET
ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata (AIM)
VICTORIA, Sept. 23, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces its AbthenaTM bispecific antibody platform and the complementary ArtemisTM Intelligence Metadata (AIM)TM suite.
Aug 28, 2019 06:33 pm ET
ImmunoPrecise Antibodies' Annual Revenues Increase 100% to $10,926,268 Million
VICTORIA, Aug. 28, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for the year ended April 30, 2019.  The financial statements and related Management's Discussion and Analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Aug 01, 2019 08:00 am ET
ImmunoPrecise's Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee
VICTORIA, Aug. 1, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces the launch of its High Value Target Scientific Committee which will strengthen the scientific oversight and methodological practice within Talem. The Committee consists of a selection of internationally recognized visionary scientists and experts from a broad range of disciplines. Their task is to assist in the planning of Talem's partnerships, in particular, they are charged with overseeing the development of the scientific pipeline including reviewing and s
Jul 15, 2019 08:30 am ET
ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals
VICTORIA, July 15, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF), an industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that it has entered into a new antibody discovery collaboration with Entos Pharmaceuticals Inc., to develop a therapeutic candidate against an undisclosed, immuno-oncology target, by leveraging ImmunoPrecise's proprietary B cell Select™ platform.
Jun 26, 2019 08:15 am ET
ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform
VICTORIA, June 26, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF), the industry leader in the discovery of novel, therapeutic monoclonal antibodies, announces that from this point forward it will guarantee the success of campaigns powered by its proprietary B cell Select™ Antibody Discovery platform. 
May 30, 2019 08:30 am ET
ImmunoPrecise Antibodies Announces an Unprecedented Onboarding of Pharma and Biotech Clients Using IPA's Proprietary High-Throughput B-Cell Select™ and DeepDisplay™
The Diversified Offerings of 9 Transgenic Animal Strains Platforms supports Solid Growth in Drug Discovery Services
Apr 25, 2019 08:30 am ET
ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc Growth Factor
VICTORIA, April 25, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF)
Apr 16, 2019 08:30 am ET
ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, April 16, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today that Jennifer Bath, President and CEO of ImmunoPrecise Antibodies, will present at the upcoming 2019 Bloom Burton & Co. Healthcare Investor Conference.
Apr 11, 2019 08:30 am ET
ImmunoPrecise Appoints Andy Nixon to Board of Directors
VICTORIA, April 11, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that it has appointed Andy Nixon, Vice President of Biotherapeutics Molecule Discovery at Boehringer Ingelheim, as a member of its board of directors.
Apr 09, 2019 08:30 am ET
TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeutic Antibodies
VICTORIA, April 9, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce the extension of its collaboration with TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases. The alliance is focused on the discovery of novel human monoclonal antibodies against three undisclosed therapeutically-relevant ion-channels.
Apr 04, 2019 08:30 am ET
ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics
VICTORIA, April 4, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary, Talem Therapeutics (Talem). Talem is focused on the discovery and development of next-generation, fully-human, monoclonal therapeutic antibodies targeting neurology, immuno-oncology, gastroenterology, inflammation, and rare/specialty diseases. Using proprietary antibody discovery platforms and innovative technologies, Talem will be producing a rich pipeline of high quality and distinct an
Apr 03, 2019 08:32 pm ET
ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market
VICTORIA, April 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares have been approved for trading on the OTCQB® Venture Market ("OTCQB") in the United States. The Company commences trading under the symbol "IPATF", as announced by the OTC Markets Group ("OTC") on April 04, 2019.
Apr 02, 2019 08:54 am ET
ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform
ImmunoPrecise Launches Large-Scale Discovery Program with US Pharma Company
Mar 27, 2019 06:26 pm ET
ImmunoPrecise Antibodies Reports Record Q3 2019 Financials Results
- Revenues Up 228% For The First 9 Months of Fiscal 2019
Mar 27, 2019 08:00 am ET
Positive Results and New Technology Give Rise to Antibody Dominance
Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance. GELifesciences.com, talking about...
Mar 15, 2019 01:47 pm ET
ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV
VICTORIA, BC, March 15, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) today announces that Jos Raats, Ph.D., has resigned from the position of Managing Director of ModiQuest Research B.V. in order to pursue his duties as CEO of Absano BV, a company developing antibodies for therapeutic and diagnostic applications in the field of cancer, autoimmunity, and infection, along with TACPA B.V., a clinical stage company focusing on a phase I anti-inflammatory antibody candidate directed at multiple diseases, and which was developed using Mod
Feb 28, 2019 08:00 am ET
ImmunoPrecise Antibodies Announces DTC Eligibility
VICTORIA, BC, Feb. 28, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.
Feb 21, 2019 07:30 am ET
ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies
VICTORIA, Feb. 21, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) has received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical Research, Inc., which currently operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute (NCI). Under the subcontract, IPA will discover and produce rabbit monoclonal antibodies using its proprietary B-Cell Select platform.  
Feb 19, 2019 07:30 am ET
ImmunoPrecise Antibodies Collaborates with FIND to Help Advance New TB Diagnostic Test
VICTORIA, Feb. 19, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration project with the Foundation for Innovative New Diagnostics (FIND) where IPA developed rabbit monoclonal antibodies (mAbs) for assessment in FIND's sensitive new immunoassay diagnostic test for tuberculosis (TB). IPA developed rabbit monoclonal antibodies, using its B cell Select platform, that recognize lipoarabinomannan (LAM), a lipopolysaccharide target and biomarker for TB that can be excreted in th
Feb 14, 2019 08:00 am ET
Second US Office for ImmunoPrecise Antibodies, Ltd. in Cambridge, Massachusetts
VICTORIA, Feb. 14, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced that they have opened a new subsidiary office in Cambridge, Massachusetts.
Feb 05, 2019 07:45 am ET
ImmunoPrecise Antibodies Ltd. Increases Antibody Discovery Capabilities with Addition of Integrated Laboratory Equipment for High-throughput Antibody Screening
VICTORIA, Feb. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced the purchase of its second state-of-the-art Intellicyt® iQue Screener PLUS for high-throughput cell-based screening.
Jan 14, 2019 07:30 am ET
ImmunoPrecise Appoints Lisa Helbling as Chief Financial Officer
VICTORIA, Jan. 14, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has appointed Lisa Helbling as Chief Financial Officer.
Jan 03, 2019 12:33 pm ET
ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 7-10, 2019
VICTORIA, Jan. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE IPA) (OTC PINK IPATF) announced today IPA will be in San Francisco during the J.P. Morgan 37th Annual Healthcare Conference events running from January 7-10, 2019 in San Francisco, California.
Dec 31, 2018 03:01 pm ET
Immunoprecise Doubles Q2 Revenue From Q2 2017
VICTORIA, Dec. 31, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "ImmunoPrecise") (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for Q2 ended October 31, 2018. The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Dec 26, 2018 07:30 am ET
ImmunoPrecise Hires Jason Orloske as Vice President Operations
VICTORIA, Dec. 26, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for ImmunoPrecise Antibodies Global Division reporting directly to Dr. Jennifer Bath, CEO and President.
Nov 21, 2018 05:33 pm ET
ImmunoPrecise Announces Results of Annual General Meeting
VICTORIA, Nov. 21, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that all resolutions were passed by the shareholders at its annual general meeting ("AGM") held in Vancouver, British Columbia on November 20, 2018.
Oct 29, 2018 08:00 am ET
ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform
Closes Conversion of $1.377 Million of Debentures
Oct 15, 2018 08:30 am ET
ModiQuest to Offer Ligand's OmniAb Service in Europe
VICTORIA, Oct. 15, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that ModiQuest® Research, an ImmunoPrecise Company, is now an OmniAb approved CRO, which enables ImmunoPrecise to offer OmniAb services in both the US and Europe. This approval allows ImmunoPrecise to further expand its human therapeutic antibody discovery platform in Europe.
Oct 09, 2018 08:30 am ET
ImmunoPrecise Signs Large Pharma Antibody Development Agreement
VICTORIA, Oct. 9, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed an agreement and initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company, to discover novel antibodies using ImmunoPrecise's proprietary hybridoma technology.
Oct 02, 2018 08:30 am ET
ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms
VICTORIA, Oct. 2, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offerings through their recent expansion in Europe. Through construction and screening of scFv and VHH phage display libraries, ImmunoPrecise is able to generate monoclonal antibodies, in a diverse range of animal species, against complex protein structures.  
Oct 01, 2018 08:45 am ET
ImmunoPrecise Antibodies' Q1 Revenues Increase 386% Over Q1 2017
VICTORIA, Oct. 1, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise") (TSX Venture: IPA) (Pink Sheets: IPATF) today reports its financial results for Q1 ended July 31, 2018.  The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Sep 28, 2018 08:30 am ET
ImmunoPrecise Closes Oversubscribed Private Placement Raising $9.1M
VICTORIA, Sept. 28, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 9,102,500 units ("Units") of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $9,102,500 (the "Financing").  Due to strong investor demand, the Financing was oversubscribed by $2,102,500.
Sep 21, 2018 09:29 am ET
The Centre for Drug Research and Development (CDRD) selected ImmunoPrecise's Chief Scientific Officer, Dr. Deanna Dryhurst as member of the CDRD Academy Executive Institute.
VICTORIA, Sept. 21, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF)  is proud to announce that our CSO, Dr. Deanna Dryhurst, has been selected as part of The CDRD Academy's Executive Institute inaugural cohort.
Aug 30, 2018 08:30 am ET
ImmunoPrecise and Harbour Antibodies Announce Technology Co-Offering Agreement for Next-Generation Fully-Human Antibody Discovery
Co-offering Agreement combines ImmunoPrecise's advanced hybridoma plus B cell screening and sorting services with Harbour Antibodies' patented H2L2 transgenic mouse platform
Aug 29, 2018 09:00 am ET
ImmunoPrecise Antibodies' Annual Revenues Increase 106% to $5.4 Million
VICTORIA, BC, Aug. 29, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise") (TSXV: IPA) (Pink Sheets: IPATF) today reports its financial results for the year ended April 30, 2018.  The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Aug 28, 2018 03:16 pm ET
ImmunoPrecise Increases Private Placement Financing to $7 Million
VICTORIA, Aug. 28, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private placement financing (see news release dated August 22, 2018) to 7,000,000 units ("Units") of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $7,000,000 (the "Financing").
Aug 22, 2018 04:00 pm ET
ImmunoPrecise Announces $2 Million Financing
VICTORIA, Aug. 22, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of 2,000,000 units ("Units") of ImmunoPrecise at a price of $1.00 per Unit for gross proceeds of $2,000,000 (the "Financing").
Aug 20, 2018 05:30 pm ET
ImmunoPrecise Announces the Resignation of Director
VICTORIA, Aug. 20, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that Mr. Guy Champagne, has resigned from his position as a director, effective immediately, and will be joining ImmunoPrecise's Advisory Board.  The Board of Directors would like to thank Mr. Champagne for all of his efforts as a director and looks forward to working with Guy in his role as an Advisory Board Member.
Jul 18, 2018 01:00 pm ET
ImmunoPrecise Accelerates the Launch of its European, Full-service, B-cell Facility
VICTORIA, July 18, 2018 /CNW/ - To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its ModiQuest Research division in Oss, the Netherlands.
Jun 19, 2018 08:45 am ET
ImmunoPrecise Closes Private Placement Financing
VICTORIA, June 19, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 875,000 units ("Units") of ImmunoPrecise at a price of $0.80 per Unit for gross proceeds of $700,000 (the "Financing").
May 29, 2018 08:30 am ET
ImmunoPrecise Announces Private Placement Financing
VICTORIA, May 29, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of 750,000 units ("Units") of ImmunoPrecise at a price of $0.80 per Unit for gross proceeds of $600,000 (the "Financing").
May 24, 2018 05:11 pm ET
ImmunoPrecise Appoints Jennifer Bath to Board of Directors and Expands Senior Leadership to Further Global Growth
VICTORIA, BC, May 24, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, as part of its annual review of management and board members, it has appointed Jennifer L. Bath, the Chief Executive Officer and President of ImmunoPrecise, as a member of its board of directors.
May 18, 2018 08:30 am ET
ImmunoPrecise Opens U.S. Headquarters in Fargo, North Dakota
VICTORIA, May 18, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its U.S. Headquarters in Fargo, North Dakota.
Apr 27, 2018 08:46 am ET
ImmunoPrecise Opens New Full Service B-Cell Facility
VICTORIA, April 27, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell facility offering B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including GPCRs and other multi-membrane spanning proteins.  The immediate benefits to ImmunoPrecise is that B-cell services will now be provided in-house and it greatly increases the profit margin of the services offered by IPA.
Apr 06, 2018 03:58 pm ET
ImmunoPrecise Announces Oversubscription to Debenture Financing
VICTORIA, April 6, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. ("ImmunoPrecise") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the "Debentures") financing in the principal amount of $250,000.  In total, ImmunoPrecise issued $4,252,000 of Debentures under the entire financing.
Apr 06, 2018 08:30 am ET
ImmunoPrecise Acquires ModiQuest Research BV
Immediately Accretive by Adding EBITA of Approximately C$750,000 with Increased Synergies, Scale and Efficiency
Apr 06, 2018 08:30 am ET
ImmunoPrecise Acquires ModiQuest Research BV
Immediately Accretive by Adding EBITA of Approximately C$750,000 with Increased Synergies, Scale and Efficiency...
Mar 28, 2018 07:24 pm ET
Immunoprecise Antibodies Delivers Record Quarterly Revenue of $1.723 Million and Increases Gross Margins To 54%
VICTORIA, March 28, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX Venture: IPA, OTC PINK: IPATF) today reports its financial results for the third quarter ended January 31, 2018.  The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Mar 16, 2018 08:30 am ET
ImmunoPrecise enters into definitive agreement to acquire ModiQuest Research BV
VICTORIA, March 16, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "Immunoprecise") (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has entered into the definitive share purchase agreement (the "Definitive Agreement") to acquire all of the issued and outstanding shares of ModiQuest Research B.V. ("ModiQuest") and Immulease B.V. ("Immulease"). 
Feb 08, 2018 07:30 am ET
ImmunoPrecise appoints new President and CEO
VICTORIA, BC, Feb. 8, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the appointment of Dr. Jennifer Bath, as the new President and CEO of the Company effective February 21, 2018.
Jan 27, 2018 10:02 am ET
ImmunoPrecise Antibodies Grants Stock Options
VICTORIA, Jan. 27, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSXV:IPA, Pink Sheets:IPATF) reports that, pursuant to the Company's Stock Option Plan, the Board of Directors has authorized the granting of incentive stock options to directors and officers of the Company to acquire an aggregate of 1,750,000 common shares of the Company.  The options have an exercise price of $0.65 per share and expire five years from the date of grant.
Jan 22, 2018 07:30 am ET
ImmunoPrecise to strategically invest in foundational Next Generation Antibody Discovery technology
VICTORIA, Jan. 22, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a letter of intent with Single Cell Technology, Inc. ("Single Cell") whereby the Company has agreed to strategically invest $5M (USD) in the expansion and development of production capability for Single Cell's patented foundational technology (the "Investment").  The Investment will result in the Company owning approximately 10% of the issued and outstanding shares of Single Cell.
Jan 18, 2018 08:08 am ET
ImmunoPrecise Engages San Francisco Based LightPath Capital as a Key Partner in its Financing Strategy
VICTORIA, BC, Jan. 18, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has engaged LightPath Capital, Inc. ("LightPath") to act as its financial advisor and placement agent with respect to certain investment banking and related matters.
Jan 18, 2018 08:08 am ET
ImmunoPrecise Engages San Francisco Based LightPath Capital as a Key Partner in its Financing Strategy
VICTORIA, BC, Jan. 18, 2018 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has engaged LightPath Capital, Inc. ("LightPath") to act as its financial advisor and placement agent with respect to certain investment banking and related matters. ...
Dec 29, 2017 03:30 pm ET
ImmunoPrecise Antibodies Reports Second Quarter Results
VICTORIA, Dec. 29, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSXV: IPA, Pink Sheets: IPATF) today reports its financial results for the second quarter ended October 31, 2017 and provides a business update.  The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Dec 29, 2017 10:42 am ET
ImmunoPrecise to Strategically Invest in SERPINx B.V.
VICTORIA, Dec. 29, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with SERPINx B.V. ("SERPINx") to strategically invest in the development of recombinant protease inhibitors to treat bradykinin mediated diseases (the "Investment").
Dec 28, 2017 03:32 pm ET
ImmunoPrecise to Acquire Preclinics GmbH
VICTORIA, Dec. 28, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with Preclinics GmbH ("Preclinics") whereby the Company has agreed to acquire all of the issued and outstanding shares of Preclinics (the "Transaction").
Dec 22, 2017 04:18 pm ET
IIROC Trade Resumption - ImmunoPrecise Antibodies Ltd.
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2017) - Trading resumes in:
Dec 22, 2017 03:39 pm ET
IIROC Trading Resumption - SLG; IPA
VANCOUVER, Dec. 22, 2017 /CNW/ - Trading resumes in:
Dec 22, 2017 02:22 pm ET
ImmunoPrecise to acquire Crossbeta Research BV
VICTORIA, BC, Dec. 22, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with Crossbeta Biosciences B.V. ("Crossbeta") whereby the Company has agreed to acquire all of the issued and outstanding shares of Crossbeta (the "Transaction").
Dec 22, 2017 09:18 am ET
IIROC Trade Halt - ImmunoPrecise Antibodies Ltd.
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2017) - The following issues have been halted by IIROC:
Dec 22, 2017 08:24 am ET
IIROC Trading Halt - IPA
VANCOUVER, Dec. 22, 2017 /CNW/ - The following issues have been halted by IIROC:
Dec 19, 2017 07:30 am ET
ImmunoPrecise Adds Scientific Depth to its Board Of Directors
VICTORIA, BC, Dec. 19, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce the appointment of Dr. Robert Burke to the Company's Board of Directors. 
Dec 07, 2017 07:30 am ET
ImmunoPrecise to Acquire ModiQuest Research BV
VICTORIA, Dec. 7, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with ModiQuest Research BV ("ModiQuest") whereby the Company has agreed to acquire all of the issued and outstanding shares of ModiQuest (the "Transaction"). 
Dec 07, 2017 07:30 am ET
ImmunoPrecise to Acquire ModiQuest Research BV
VICTORIA, Dec. 7, 2017 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with ModiQuest Research BV ("ModiQuest") whereby the Company has agreed to acquire all of the issued and outstanding shares of ModiQuest (the "Transaction").  ...
Nov 20, 2017 08:30 am ET
ImmunoPrecise Realigns Senior Management
VICTORIA, Nov. 20, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the realignment of its senior management team as Dr. James Kuo, Chair of the Board, assumes the interim position of President of the Company, Robert Beecroft, founder and director assumes the role of CEO to further strategically position the Company together with its European partner, U-Protein Express B.V. to pursue expansion into the European market and growth initiatives globally.  Thomas D'Orazio will remain as an IPA director.  Dr. Oren Beske will be pursuing other
Oct 02, 2017 09:30 am ET
ImmunoPrecise to Acquire QVQ Holdings BV and Reports Growth Results
VICTORIA, Oct. 2, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with QVQ Holdings BV ("QVQ") whereby the Company has agreed to acquire all of the issued and outstanding shares of QVQ (the "Transaction").  Currently, U-Protein Express B.V., a wholly owned subsidiary of the Company owns 37% of the issued and outstanding shares of QVQ. 
Sep 29, 2017 07:00 pm ET
ImmunoPrecise Antibodies Reports Q1 2018 Results
ImmunoPrecise Develops Humanizing Platforms to Significantly Grow Core Business Increases Operational Efficiency and Expands Capacity to Scale Quickly VICTORIA, Sept. 29, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) today reports its financial results for the first quarter ended July 31, 2017 and provides a business update.  The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Sep 18, 2017 09:15 am ET
ImmunoPrecise Awarded First Commercial Humanized Antibody Project from Established Biotech Company and Grants Stock Options
VICTORIA, Sept. 18, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "ImmunoPrecise") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has been awarded its first significant commercial humanizing project from an established biotech company. 
Sep 07, 2017 10:18 am ET
ImmunoPrecise Antibodies announces Dr. Oren Beske joining the Executive Leadership Team and AGM results
VICTORIA, BC, Sept. 7, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce that Oren Beske, Ph.D. has joined the company as of September 1, 2017 and will be appointed the President of the ImmunoPrecise Antibodies USA Subsidiary ("the Subsidiary"). Dr. Beske holds a Ph.D in Cellular Biology from University of California, San Francisco and BS degrees in both Physiology and Biochemistry from California State University, Long Beach. Dr. Beske comes to the Company from Aragen Biosciences (Morgan Hill, California) where he served a
Aug 29, 2017 09:15 am ET
ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies
VICTORIA, Aug. 29, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), announces the Company is now an approved contract research organization ("CRO") for developing human monocolonal antibodies using the OmniAb® platform of transgenic mice and rats. 
Aug 24, 2017 09:15 am ET
ImmunoPrecise Antibodies Reports 2017 Annual Results - Revenues up 39% Over Fiscal 2016
VICTORIA, Aug. 24, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA)(OTC PINK: IPATF) yesterday reported its financial results for the fourth quarter ended April 30, 2017 and provides a business update.  The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Aug 23, 2017 11:05 am ET
ImmunoPrecise completes acquisition of U-Protein and private placement of $5.25 million
VICTORIA, Aug. 23, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has completed the acquisition of U-Protein Express BV ("U-Protein") whereby the Company has acquired all of the issued and outstanding shares of U-Protein (the "Transaction") and complete a non-brokered private placement of $5,250,000 (Cdn) (the "Financing").  This Transaction completes the first strategic acquisition for the Company.
Aug 11, 2017 09:15 am ET
ImmunoPrecise Signs Definitive Agreement With U-Protein
VICTORIA, Aug. 11, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, further to its news release dated July 4, 2017, it has signed a definitive agreement with U-Protein Express BV ("U-Protein") whereby the Company will acquire all of the issued and outstanding shares of U-Protein (the "Definitive Agreement").
Aug 03, 2017 09:15 am ET
ImmunoPrecise Announces Expansion into Humanizing Technologies and Platforms
VICTORIA, Aug. 3, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has completed significant steps that enhance its ability to deliver humanized monoclonal antibodies to customers. 
Aug 02, 2017 04:58 pm ET
ImmunoPrecise Increases Financing to $5.25 Million
VICTORIA, Aug. 2, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to announce that it has further increased its previously announced non-brokered private placement financing (see press release dated July 4, 2017 and July 24, 2017) to 5,250,000 shares  (each, a "Share") at a price of $1.00 per Share for gross proceeds of up to $5,250,000.
Jul 26, 2017 09:15 am ET
ImmunoPrecise Enters Agreement to Develop Immune-Contraceptive Vaccines for Wildlife
VICTORIA, July 26, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company")(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the engagement of TerraMar Environmental Research Ltd. ("TerraMar") for the purposes of developing immune-contraceptive vaccines for overabundant wildlife populations. 
Jul 24, 2017 09:15 am ET
ImmunoPrecise increases financing to $5.1 million
VICTORIA, July 24, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to announce that it has  increased its previously announced non-brokered private placement financing (see press release dated July 4, 2017)  to 5,100,000 shares   (each, a "Share") at a price of $1.00 per Share for gross proceeds of up to $5,100,000.
Jul 04, 2017 01:02 pm ET
IIROC Trading Resumption - IPA
VANCOUVER, July 4, 2017 /CNW/ - Trading resumes in:
Jul 04, 2017 12:52 pm ET
ImmunoPrecise to acquire U-Protein and announces $4,000,000 financing
VICTORIA, July 4, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with U-Protein Express BV ("U-Protein") whereby the Company has agreed to acquire all of the issued and outstanding shares of U-Protein (the "Transaction").  This represents a key step in the board of directors' continued review of potential strategic acquisition opportunities for the Company. 
Jun 30, 2017 03:34 pm ET
IIROC Trading Halt - IPA
VANCOUVER, June 30, 2017 /CNW/ - The following issues have been halted by IIROC:
Jun 22, 2017 09:45 am ET
ImmunoPrecise Antibodies Expands Western Sales Team With New Regional Sales Manager
VICTORIA, June 22, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company")(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the expansion of its Western sales organization by adding Mazyar (Mazy) Marjani as its new Western Regional Sales Manager.   
Jun 05, 2017 09:30 am ET
ImmunoPrecise Antibodies opens new antibody production laboratory to increase manufacturing capacity
VICTORIA, June 5, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company")(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the opening of its new 3,200 square foot state of the art antibody production laboratory at Vancouver Island Technology Park that has been designed in conjunction with Low Hammond Rowe Architects.  The addition of this new laboratory:
Apr 11, 2017 09:15 am ET
ImmunoPrecise begins humanized antibody development
VICTORIA, April 11, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company")(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the launch of a new research initiative.
Mar 30, 2017 05:08 pm ET
ImmunoPrecise Antibodies reports Q3 2017 financial results - revenues up 70% for the first nine months of fiscal 2017
VICTORIA, March 30, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), today reports its financial results for the third quarter ended January 31, 2017 and provides a business update. The financial statements and related management's discussion and analysis ("MD&A") can be viewed on SEDAR at www.sedar.com.
Mar 28, 2017 08:12 pm ET
ImmunoPrecise Adds Two Key Senior Executives to Support Growth
VICTORIA, March 28, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), a life sciences technology and product company engineering custom antibodies, today announced two key, senior-level additions to its executive leadership team to support growth.
Mar 09, 2017 08:30 am ET
ImmunoPrecise adds Dr. David Kroeger as Senior Scientist; New US trading symbol
VICTORIA, March 9, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF), a life sciences technology and product company engineering custom antibodies, is pleased to announce that David Kroeger, PhD. has joined the Company as Senior Scientist. 
Mar 01, 2017 08:30 am ET
ImmunoPrecise appoints Contact Financial for investor relations and launches new website for its Custom Antibody Services
VICTORIA, March 1, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: TQURF), a life sciences technology and product company engineering custom antibodies, announced that it has appointed Contact Financial ("Contact") as its investor relations firm.  Contact will assist the Company with the development and execution of a comprehensive strategic communications program. 
Dec 28, 2016 04:09 pm ET
IIROC Trading Resumption - IPA
VANCOUVER, Dec. 28, 2016 /CNW/ - Trading resumes in: